Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh

Leukemia Research

Volumn 23, Issue 10, 1999, Pages 881-888

  Wall, Nathan R ^a   Mohammad, Ramzi M ^a   Al Katib, Ayad M ^a  

^a Division of Hematology and Oncology   (United States)

Author keywords

7 Amino actinomycin D; Acute lymphocytic leukemia cells; Auristatin PE; Bax; Bcl 2; Bryostatin 1; Dolastatin 10

Indexed keywords

BRYOSTATIN 1; PROTEIN BAX; PROTEIN BCL 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; HUMANS; LACTONES; LEUKEMIA, B-CELL, ACUTE; MACROLIDES; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0032877433     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00108-3     Document Type: Article

References (52)

1. Uren A.G., Vaux D.L. Molecular and clinical aspects of apoptosis. Pharmacol. Ther. 72:1996;37-50.
2. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer. 26:1972;239-257.
3. Raff M.C. Social controls on cell survival and cell death. Nature. 356:1992;397-400.
4. Reed J.C. Dysregulation of apoptosis in non-Hodgkin's lymphomas: toward a molecular understanding of bcl-2. Advances in Leukemia and Lymphoma. 7:1997;1-15.
5. Rowan S., Fisher D.E. Mechanisms of apoptotic cell death. Leukemia. 11:1997;457-465.
6. Findley H.W., Gu L., Yeager A.M., Zhou M. Expression and regulation of bcl-2, bcl-xl, and bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 39:1997;2986-2993.
7. Wang S., Vrana J.A., Bartimole T.M., Freemerman A.J., Jarvis W.D., Kramer L.B. et al. Agents that down-regulate or inhibit protein kinase c circumvent resistance to 1-b-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress bcl-2. Mol. Pharm. 52:1997;1000-1009.
8. Dive C., Hickman J.A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer. 64:1991;192-196.
9. O'Connor P.M., Wassermann K., Sarang M., Magrath I., Bohr V.A., Kohn K.W. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res. 51:1991;6550-6557.
10. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
11. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442.
12. Goldring O. Therapeutics: a glimpse of the future. Nature. 392:1998;420.
13. Consolini R., Pui C.H., Behm F.G., Raimondi S.C., Campana D. In vitro cytotoxicity of docetaxel in childhood acute leukemias. J. Clin. Oncol. 16:1998;907-913.
14. Kimura C., Zhao Q.L., Kondo T., Amatsu M., Fujiwara Y. Mechanism of UV-induced apoptosis in human leukemia cells: roles of Ca2+/Mg(2+)-dependent endonuclease, caspase-3, and stress-activated protein kinases. Exp. Cell. Res. 239:1998;411-422.
15. Lotem J., Peled-Kamar M., Groner Y., Sachs L. Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines. Proc. Natl. Acad. Sci. USA. 93:1996;9166-9171.
16. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., Lejeune F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 4:1998;408-414.
17. Buske C., Becker D., Feuring-Buske M., Hannig H., Wulf G., Schafer C. et al. TGF-beta inhibits growth and induces apoptosis in leukemic B cell precursors. Leukemia. 11:1997;386-392.
18. Messineo C., Jamerson M.H., Hunter E., Braziel R., Bagg A., Irving S.G. et al. Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood. 91:1998;2443-2451.
19. Pisani F., Del Poeta G., Aronica G., Venditti A., Caravita T., Amadori S. In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. Ann. Hematol. 75:1997;145-147.
20. Bocchia M., Xu Q., Wesley U., Xu Y., Korontsvit T., Loganzo F. et al. Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Leuk. Res. 21:1997;439-447.
21. Trapani J.A., Browne K.A., Smyth M.J., Jans D.A. Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J. Biol. Chem. 271:1996;4127-4133.
22. Barge R.M., Willemze R., Vandenabeele P., Fiers W., Beyaert R. Differential involvement of caspases in apoptosis of myeloid leukemic cells induced by chemotherapy versus growth factor withdrawal. FEBS Lett. 409:1997;207-210.
23. Sieg S., Huang Y., Kaplan D. Viral regulation of CD95 expression and apoptosis in T lymphocytes. J. Immunol. 159:1997;1192-1199.
24. Furuke K., Sasada T., Ueda-Taniguchi Y., Yamauchi A., Inamoto T., Yamaoka Y. et al. Role of intracellular redox status in apoptosis induction of human T-cell leukemia virus type I-infected lymphocytes by 13-cis-retinoic acid. Cancer Res. 57:1997;4916-4923.
25. Quillet-Mary A., Jaffrezou J.P., Mansat V., Bordier C., Naval J., Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J. Biol. Chem. 272:1997;21388-21395.
26. Gala J.L., Vermylen C., Cornu G., Ferrant A., Michaux J.L., Philippe M. et al. High expression of Bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. Ann. Hematol. 69:1994;17-24.
27. Coustan-Smith E., Kitanaka A., Pui C.H., McNinch L., Evans W.E., Raimondi S.C. et al. Clinical relevance of Bcl-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 87:1996;1140-1146.
28. Wall NR, Mohammad RM, Reddy KB, Al-Katib AM. Bryostatin 1 induces down-regulation and ubiquitination of bcl-2 in the human acute lymphoblastic leukemia cell line, Reh. (submitted).
29. Salomons G.S., Brady H.J., Verwijs-Janssen M., Van Den Berg J.D., Hart A.A. et al. The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int. J. Cancer. 71:1997;959-965.
30. Koziner B., Stavnezer J., Al-Katib A. Surface immunoglobulin expression by a 'common' acute lymphoblastic leukemia (ALL) cell line (Reh). Clin. Immunopath. 37:1985;135-141.
31. Pettit G.R., Herald S.L., Doubek D.L., Arnold E., Clardy J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 104:1982;6846-6848.
32. Stone R.M., Sariban E., Pettit G.R., Kufe D.W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 72:1988;208-213.
33. Kiss Z., Deli E., Girard P.R., Pettit G.R., Kuo J.F. Comparative effects of polymyxin B, phorbol ester and bryostatin on protein phosphorylation, protein kinase C translocation, phospholipid metabolism and differentiation of HL60 cells. Biochem. Biophys. Res. Commun. 146:1987;208-215.
34. Jones R.J., Sharkis S.J., Miller C.B., Towinsky E.K., Burke P.J., May W.S. Bryostatin 1, a unique biological response modifier: antileukemic activity in vitro. Blood. 75:1990;1319-1323.
35. Tuttle T.M., Inge T.H., Bethke K.P., McCrady C.W., Pettit G.R., Bear H.D. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res. 52:1992;548-553.
36. Bai R., Roach M.C., Jayaram S.K., Barkoczy J., Pettit G.R., Luduena R.F. et al. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol. 45:1993;1503-1515.
37. Pettit G.R., Srirangam J.K., Barkoczy J., Williams M.D., Durkin K.P., Boyd M.R. et al. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anti-Cancer Drug Design. 10:1995;529-544.
38. Hill B.T., Whelan R.D.H. Comparative cell killing and kinetic effects of vincristine or vindesine in mammalian cell lines. J. Natl. Cancer Inst. 67:1981;437-443.
39. Jackson D.V., Bender R.A. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res. 39:1979;4346-4349.
40. Jordan M.A., Thrower D., Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 51:1991;2212-2222.
41. Philpott N.J., Turner A.J.C., Scopes J., Westby M., Marsh J.C.W., Gordon-Smith E.C. et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood. 87:1996;2244-2251.
42. Maki A., Diwakaran H., Redman B., Al-Asfar S., Pettit G.R., Mohammad R.M. et al. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs. 6:1995;392-397.
43. Mohammad R.M., Varterasian M.L., Almatchy V.P., Hannoudi G.N., Pettit G.R., Al-Katib A. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Clin. Cancer Res. 4:1998;1337-1343.
44. Mohammad R.M., Pettit G.R., Almatchy V.P., Wall N., Varterasian M., Al-Katib A. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Anti-Cancer Drugs. 9:1998;21-29.
45. Ito T., Deng X., Carr B., May W.S. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 272:1997;11671-11673.
46. Deng X., Ito T., Carr B., Mumby M., May W.S. Reversible phosphorylation of bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J. Biol. Chem. 273:1998;34157-34163.
47. Cotter F.E., Johnson P., Hall P., Pocock C., Al Mahdi N., Cowell J.K. et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 9:1994;3049-3055.
48. Kitada S., Takayama S., De Riel K., Tanaka S., Reed J.C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev. 4:1994;71-79.
49. Campos L., Sabido O., Rouault J.P., Guyotat D. Effects of Bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood. 84:1994;595-600.
50. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C. et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096.
51. Oltvai Z., Milliman C., Korsmeyer S. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
52. Yin X., Oltvai Z., Korsmeyer S. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 369:1994;321-323.